Drug
Lumasiran
Lumasiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lumasiran NCT03681184 | Phase 3 | Primary Hyperoxaluria Type 1 (PH1) |
| Lumasiran NCT03905694 | Phase 3 | Primary Hyperoxaluria |
| Lumasiran NCT05161936 | Phase 2 | Recurrent Calcium Oxalate Kidney Stone Disease |
| Lumasiran NCT03350451 | Phase 2 | PH1 |
Latest
No recent events.
Follow Lumasiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.